| AICE | angiotensin I converting enzyme |
|---|---|
| SACE | serum angiotensin-converting enzyme |
| CEI | character education inquiry; converting enzyme inhibitor |
| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| receptors, angiotensin | Cell surface proteins that bind angiotensins and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
|---|---|
| renin-angiotensin-aldosterone system | The hormones, renin, angiotensin, and aldosterone work together to regulate blood pressure. A sustained fall in blood pressure causes the kidney to release renin. This is converted to angiotensin in the circulation. Angiotensin then raises blood pressure directly by arteriolar constriction and stimulates adrenal gland to produce aldosterone which promotes sodium and water retention by kidney, such that blood volume and blood pressure increase. (05 Mar 2000) |
| renin-angiotensin system | <physiology> A system consisting of renin, angiotensin-converting enzyme, and angiotensin II. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming angiotensin I. The converting enzyme contained in the lung acts on angiotensin I in the plasma converting it to angiotensin II, the most powerful directly pressor substance known. It causes contraction of the arteriolar smooth muscle and has other indirect actions mediated through the adrenal cortex. (25 Jun 1999) |
| 1-sarcosine-8-isoleucine angiotensin II | <chemical> An angiotensin II analog which acts as a highly specific inhibitor of angiotensin II. Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents. Chemical name: Angiotensin II, 1-(N-methylglycine)-8-L-isoleucine- (12 Dec 1998) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |